Aarti Drugs Limited
NSE: AARTIDRUGSMarket Closed • NSE
Day range
52 week range
Aarti Drugs Limited closed at INR396.35 (-0.03%) on volume 0.39x its 20-day average, trading 25.78% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -9.1% QoQ
2026-02-09
DIVIDEND Announced
Interim Dividend - Rs 2 Per Share
2025-02-04
DIVIDEND Announced
Interim Dividend - Re 1 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.37x
High Cash Flow Conversion: CFO/PAT averaged 1.3x over last 3 years
Attractive Valuation: P/E of 18.9x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 09 Feb 2026 | Dividend | ₹2.00 / share | — | 09 Feb 2026 |
| 04 Feb 2025 | Dividend | ₹1.00 / share | — | 04 Feb 2025 |
| 05 Sept 2024 | Buy Back | Buy Back | — | 05 Sept 2024 |
| 06 Feb 2024 | Dividend | ₹1.00 / share | — | 06 Feb 2024 |
| 04 Aug 2023 | Buy Back | Buy Back | — | 04 Aug 2023 |
| 08 Feb 2023 | Dividend | ₹1.00 / share | — | 08 Feb 2023 |
| 10 Feb 2022 | Dividend | ₹1.00 / share | — | 09 Feb 2022 |
| 01 Apr 2021 | Buyback | Buyback | — | 30 Mar 2021 |
| 04 Nov 2020 | Dividend | ₹2.50 / share | — | 03 Nov 2020 |
| 01 Oct 2020 | Bonus issue | 3:1 bonus ratio | — | 30 Sept 2020 |
| 18 Feb 2020 | Dividend | ₹2.00 / share | — | 17 Feb 2020 |
| — | Dividend | ₹1.00 / share | — | 26 Jul 2019 |
| 29 Mar 2019 | Buyback | Buyback | — | 28 Mar 2019 |
| — | Dividend | ₹1.00 / share | — | 01 Aug 2018 |
| 19 Jan 2018 | Buyback | Buyback | — | 18 Jan 2018 |
| — | Dividend | ₹1.00 / share | — | 09 Aug 2017 |
| 02 Nov 2016 | Buy Back | Buy Back | — | 01 Nov 2016 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Jul 2016 |
| 24 Mar 2016 | Dividend | ₹3.00 / share | — | 22 Mar 2016 |
| 15 Feb 2016 | Dividend | ₹1.50 / share | — | 12 Feb 2016 |
| 14 Nov 2015 | Dividend | ₹2.25 / share | — | 10 Nov 2015 |
| — | Dividend | ₹3.00 / share | — | 05 Aug 2015 |
| 25 Mar 2015 | Bonus issue | 1:1 bonus ratio | — | 24 Mar 2015 |
| 05 Feb 2015 | Dividend | ₹5.00 / share | — | 04 Feb 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]
IndiaHealthcare
Is Aarti Drugs Limited Shariah compliant?
Aarti Drugs Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (15.94%) complies with AAOIFI threshold (≤ 33%).
What is Aarti Drugs Limited's current valuation relative to peers?
Aarti Drugs Limited trades at a P/E of 18.9x compared to the sector median of 37x, and a Price-to-Book of 2.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.37x. Interest coverage is 7.2x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 0% while net profit growth averaged 0%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.